Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Opinion
Video

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Recent Videos
Marion Munk, MD, PhD, presenting slides
Related Content
Korea Institute of Science and Technology (KIST) enters technology transfer agreement with Huons BioPharma

Korea Institute of Science and Technology (KIST) enters technology transfer agreement with Huons BioPharma

Sydney M Crago
January 6th 2025
Article
Emerging insights into ocular immune-related diseases and treatment options

Emerging insights into ocular immune-related diseases and treatment options

David Hutton
January 1st 2025
Article
Ocular Therapeutix, Inc. set to present at the 43rd Annual J.P. Morgan Healthcare Conference

Ocular Therapeutix, Inc. set to present at the 43rd Annual J.P. Morgan Healthcare Conference

Sydney M Crago
December 28th 2024
Article
4DMT announces the publication of preclinical data in Investigative Ophthalmology & Visual Science

4DMT announces the publication of preclinical data in Investigative Ophthalmology & Visual Science

Sydney M Crago
December 20th 2024
Article
EssilorLuxottica enters agreement for the acquisition of Espansione Group

EssilorLuxottica enters agreement for the acquisition of Espansione Group

Sydney M Crago
December 19th 2024
Article
AMD-HALT program receives Eurostars grant for continued investigation of dry AMD gene therapy platform

AMD-HALT program receives Eurostars grant for continued investigation of dry AMD gene therapy platform

Hattie Hayes
December 16th 2024
Article
© 2025 MJH Life Sciences

All rights reserved.